Market Overview:
The global human erythropoietin market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of anemia, kidney disorders, and other diseases that require treatment with erythropoietin drugs. Additionally, the increasing demand for better-quality healthcare services is also contributing to the growth of this market. The global human erythropoietin market can be segmented on the basis of type into epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. The epoetins are currently dominating this market due to their high efficacy and safety profile as compared to other types of erythropoietins available in the market. On the basis of application, this market can be segmented into anemia, kidney disorders (renal failure and chronic renal disease), cancer (chemotherapy induced anemia), HIV/AIDS (anemia associated with HIV/AIDS), and others.
Product Definition:
Human erythropoietin is a glycoprotein hormone that is produced by the kidneys in response to decreased oxygen levels. It stimulates the production of red blood cells by the bone marrow.
Epoetin-alfa:
Epoetin-alfa is a form of human erythropoietin (EPO). It is produced by the kidney and has a growth factor property. The drug Epoetin-alfa increases the rate of red blood cell production when given to patients with chronic renal failure.
Epoetin-beta:
Epoetin- beta is a protein hormone that helps in the formation of red blood cells. It is produced by kidneys, liver and lungs. The normal range for epoetin- beta level in human body is 10 - 80 nanograms per milliliter.
Application Insights:
Anemia segment held the largest share of the global market in terms of revenue as well as volume in 2017. Anemic patients are highly dependent on R&D for the introduction of new products that can help them overcome their condition. As per WHO, approximately 10% to 15% of total population across the globe suffers from anemia-related problems at any given time during their life span.
The kidney disorders segment is expected to grow at a significant rate over the forecast period owing to increasing prevalence and incidence rates associated with this disorder coupled with rising awareness about early diagnosis and effective treatment options available for this disease currently being pursued by manufacturers globally. For instance, in June 2018 Pfizer introduced Zomacton (edomycin) injection, a once-a-week dose that reduces bacteria count while cleaning out kidneys without causing resistance or allergies among users which is expected to drive product demand over next few years.
Regional Analysis:
North America dominated the global human erythropoietin market in 2017. The region is expected to maintain its position during the forecast period. High prevalence of kidney and iron disorders, increasing geriatric population, rising awareness about DHP treatment options are some of the factors responsible for high demand for HEPO in this region.
Asia Pacific is anticipated to witness a lucrative growth rate over the forecast period owing to improving healthcare infrastructure and growing patient awareness regarding available treatment options with respect to various diseases including anemia & kidney failure (Hemodialysis-based). In addition, increasing disposable income levels coupled with rising adoption of western lifestyle will further propel regional market growth during the estimated time span.
Growth Factors:
- Increasing incidence of anemia and other blood disorders
- Growing demand for erythropoietin drugs in developing countries
- Rising number of surgical procedures requiring blood transfusions
- Technological advancements in the production of erythropoietin drugs
- increasing awareness about the benefits of erythropoietin therapy
Scope Of The Report
Report Attributes
Report Details
Report Title
Human Erythropoietin Market Research Report
By Type
Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others
By Application
Anemia, Kidney Disorders, Others
By Companies
Amgen, Johnson & Johnson, Roche, Galenica, Emcure, Kyowa Hakko Kirin, 3SBio, Biocon, LG Life Sciences
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
130
Number of Tables & Figures
91
Customization Available
Yes, the report can be customized as per your need.
Global Human Erythropoietin Market Report Segments:
The global Human Erythropoietin market is segmented on the basis of:
Types
Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Anemia, Kidney Disorders, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- Johnson & Johnson
- Roche
- Galenica
- Emcure
- Kyowa Hakko Kirin
- 3SBio
- Biocon
- LG Life Sciences
Highlights of The Human Erythropoietin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Epoetin-alfa
- Epoetin-beta
- Darbepoetin-alfa
- Others
- By Application:
- Anemia
- Kidney Disorders
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Erythropoietin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Human erythropoietin (EPO) is a hormone that stimulates the production of red blood cells. EPO is produced by the kidneys and released into the bloodstream when an individual experiences anemia.
Some of the major players in the human erythropoietin market are Amgen, Johnson & Johnson, Roche, Galenica, Emcure, Kyowa Hakko Kirin, 3SBio, Biocon, LG Life Sciences.
The human erythropoietin market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Human Erythropoietin Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Human Erythropoietin Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Human Erythropoietin Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Human Erythropoietin Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Human Erythropoietin Market Size & Forecast, 2018-2028
4.5.1 Human Erythropoietin Market Size and Y-o-Y Growth
4.5.2 Human Erythropoietin Market Absolute $ Opportunity
Chapter 5 Global Human Erythropoietin Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Human Erythropoietin Market Size Forecast by Type
5.2.1 Epoetin-alfa
5.2.2 Epoetin-beta
5.2.3 Darbepoetin-alfa
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Human Erythropoietin Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Human Erythropoietin Market Size Forecast by Applications
6.2.1 Anemia
6.2.2 Kidney Disorders
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Human Erythropoietin Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Human Erythropoietin Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Human Erythropoietin Analysis and Forecast
9.1 Introduction
9.2 North America Human Erythropoietin Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Human Erythropoietin Market Size Forecast by Type
9.6.1 Epoetin-alfa
9.6.2 Epoetin-beta
9.6.3 Darbepoetin-alfa
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Human Erythropoietin Market Size Forecast by Applications
9.10.1 Anemia
9.10.2 Kidney Disorders
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Human Erythropoietin Analysis and Forecast
10.1 Introduction
10.2 Europe Human Erythropoietin Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Human Erythropoietin Market Size Forecast by Type
10.6.1 Epoetin-alfa
10.6.2 Epoetin-beta
10.6.3 Darbepoetin-alfa
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Human Erythropoietin Market Size Forecast by Applications
10.10.1 Anemia
10.10.2 Kidney Disorders
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Human Erythropoietin Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Human Erythropoietin Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Human Erythropoietin Market Size Forecast by Type
11.6.1 Epoetin-alfa
11.6.2 Epoetin-beta
11.6.3 Darbepoetin-alfa
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Human Erythropoietin Market Size Forecast by Applications
11.10.1 Anemia
11.10.2 Kidney Disorders
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Human Erythropoietin Analysis and Forecast
12.1 Introduction
12.2 Latin America Human Erythropoietin Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Human Erythropoietin Market Size Forecast by Type
12.6.1 Epoetin-alfa
12.6.2 Epoetin-beta
12.6.3 Darbepoetin-alfa
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Human Erythropoietin Market Size Forecast by Applications
12.10.1 Anemia
12.10.2 Kidney Disorders
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Human Erythropoietin Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Human Erythropoietin Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Human Erythropoietin Market Size Forecast by Type
13.6.1 Epoetin-alfa
13.6.2 Epoetin-beta
13.6.3 Darbepoetin-alfa
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Human Erythropoietin Market Size Forecast by Applications
13.10.1 Anemia
13.10.2 Kidney Disorders
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Human Erythropoietin Market: Competitive Dashboard
14.2 Global Human Erythropoietin Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen
14.3.2 Johnson & Johnson
14.3.3 Roche
14.3.4 Galenica
14.3.5 Emcure
14.3.6 Kyowa Hakko Kirin
14.3.7 3SBio
14.3.8 Biocon
14.3.9 LG Life Sciences
